

Marie Kostine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5616261/publications.pdf>

Version: 2024-02-01

28
papers

1,806
citations

623734

14
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

2721
citing authors

#	ARTICLE	IF	CITATIONS
1	Short duration antibiotic therapy for native joint arthritis caused by <i>Neisseria</i> infection?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e230-e230.	0.9	6
2	The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis. <i>Rheumatology</i> , 2022, 61, 531-541.	1.9	2
3	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2022, 160, 134-139.	2.8	10
4	Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	4.2	1
5	Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112687.	5.6	3
6	Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2022, 89, 105403.	1.6	1
7	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.9	153
8	Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports. <i>Rheumatology</i> , 2021, 60, e47-e49.	1.9	2
9	Mismatch repair deficiency is rare in bone and soft tissue tumors. <i>Histopathology</i> , 2021, 79, 509-520.	2.9	18
10	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
11	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 506-508.	5.6	0
12	Response to: "Checkpoint inhibitors and arthritis: seeking balance between victories and defeats" by Moura and Moura. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e92-e92.	0.9	4
13	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	5.6	202
14	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 860-862.	0.9	14
15	Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. <i>RMD Open</i> , 2019, 5, e000906.	3.8	59
16	Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas. <i>PLoS Computational Biology</i> , 2019, 15, e1006826.	3.2	75
17	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
18	Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. <i>Rheumatology</i> , 2019, 58, vii68-vii74.	1.9	31

#	ARTICLE	IF	CITATIONS
19	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.8	19
20	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. <i>Onc Immunology</i> , 2018, 7, e1386828.	4.6	36
21	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 393-398.	0.9	230
22	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. <i>Laboratory Investigation</i> , 2018, 98, 41-50.	3.7	30
23	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <i>Revue De Medecine Interne</i> , 2017, 38, 513-525.	1.0	36
24	Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?. <i>European Journal of Cancer</i> , 2017, 81, 240-241.	2.8	5
25	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 119-128.	4.2	89
26	High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. <i>Clinical Sarcoma Research</i> , 2016, 6, 17.	2.3	4
27	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <i>Modern Pathology</i> , 2016, 29, 1028-1037.	5.5	84
28	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. <i>BMC Medicine</i> , 2015, 13, 211.	5.5	570